Evidence map›Paper›PMID 33082265›Full record

ArticleGut2021

Effect of IBD medications on COVID-19 outcomes: results from an international registry.

Ryan C Ungaro, Erica J Brenner, Richard B Gearry, Gilaad G Kaplan, Michele Kissous-Hunt, James D Lewis, Siew C Ng, Jean-Francois Rahier, Walter Reinisch, Flávio Steinwurz and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gut, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 172 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
172citing papers in PubMed, 7 pooled it
45.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

172 citing papers in PubMed, 7 syntheses or guidelines pooled it, 280 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Turkish IBD Organization's Position Statement on Inflammatory Bowel Disease Management Recommendations During COVID-19 Pandemic.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2021
    Guideline
  7. Guideline
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

112 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 7 countries.

Ryan C UngaroThe Henry D Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA ryan.ungaro@mssm.edu.ORCID 0000-0001-8687-3758
Erica J BrennerUniversity of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Richard B GearryDepartment of Medicine, University of Otago, Christchurch, New Zealand.
Gilaad G KaplanDepartments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.ORCID 0000-0003-2719-0556
Michele Kissous-HuntThe Henry D Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
James D LewisDivision of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Siew C NgDepartment of Medicine and Therapeutics, Institute of Digestive Disease, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Science, Chinese University of Hong Kong, Shatin, NT, Hong Kong.ORCID 0000-0002-6850-4454
Jean-Francois RahierDepartment of Gastroenterology, Université Catholique de Louvain, Yvoir, Belgium.
Walter ReinischDepartment of Medicine IV, Medical University Vienna, Vienna, Austria.ORCID 0000-0002-2088-091X
Flávio SteinwurzDepartment of Gastroenterology, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.
Fox E UnderwoodDepartments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
Xian ZhangUniversity of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Jean-Frederic Colombel *The Henry D Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Michael D Kappelman *University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Icahn School of Medicine at Mount Sinai · USUniversity of North Carolina at Chapel Hill · USUniversity of Calgary · CAChinese University of Hong Kong · HKHospital Israelita Albert Einstein · BRHospital of the University of Pennsylvania · USMedical University of Vienna · ATUCLouvain · BEUniversity of Otago · NZ

Funding

Re-Entry Supplement: Investigation of Oral Microbial Enzymes for the Detection and Treatment of Periodontal DiseaseUL1TR002489 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, SHAHEEN, NICHOLAS J · 2018 to 2022
$48.6M
Assessing Predictors of Response to Anti-Tumor Necrosis Alpha Therapy in Early Crohns DiseaseK23DK111995 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI UNGARO, RYAN · 2019 to 2023
$948k
NCATS NIH HHS UL1 TR002489NIDDK NIH HHS K23 DK111995
6 · The paper itself

Abstract

objectiveWe sought to evaluate COVID-19 clinical course in patients with IBD treated with different medication classes and combinations.

designSurveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) is a large, international registry created to monitor outcomes of IBD patients with confirmed COVID-19. We used multivariable regression with a generalised estimating equation accounting for country as a random effect to analyse the association of different medication classes with severe COVID-19, defined as intensive care unit admission, ventilator use and/or death.

results1439 cases from 47 countries were included (mean age 44.1 years, 51.4% men) of whom 112 patients (7.8%) had severe COVID-19. Compared with tumour necrosis factor (TNF) antagonist monotherapy, thiopurine monotherapy (adjusted OR (aOR) 4.08, 95% CI 1.73 to 9.61) and combination therapy with TNF antagonist and thiopurine (aOR 4.01, 95% CI 1.65 to 9.78) were associated with an increased risk of severe COVID-19. Any mesalamine/sulfasalazine compared with no mesalamine/sulfasalazine use was associated with an increased risk (aOR 1.70, 95% CI 1.26 to 2.29). This risk estimate increased when using TNF antagonist monotherapy as a reference group (aOR 3.52, 95% CI 1.93 to 6.45). Interleukin-12/23 and integrin antagonists were not associated with significantly different risk than TNF antagonist monotherapy (aOR 0.98, 95% CI 0.12 to 8.06 and aOR 2.42, 95% CI 0.59 to 9.96, respectively).

conclusionCombination therapy and thiopurines may be associated with an increased risk of severe COVID-19. No significant differences were observed when comparing classes of biologicals. These findings warrant confirmation in large population-based cohorts.MKH should be changed to MDK for co-last author line.

Indexed as

AzathioprineCOVID-19Inflammatory Bowel DiseasesMercaptopurineSARS-CoV-2Tumor Necrosis Factor InhibitorsAdultAnti-Inflammatory AgentsDrug Therapy, CombinationFemaleHumansInternational CooperationMaleRegistriesRisk AdjustmentSeverity of Illness IndexAnti-Inflammatory AgentsAzathioprineMercaptopurineTumor Necrosis Factor Inhibitorsinfectious diseaseinflammatory bowel disease

Identifiers

PMID33082265
PMCPMC8136807
OpenAlexW3094105410

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.